

### *Metastatic breast cancer– EML*

For the treatment of metastatic breast cancer, the application sought inclusion on the core list of the Model List of Essential Medicines of chemotherapy regimens utilizing cyclophosphamide, doxorubicin, paclitaxel or docetaxel, vinorelbine, capecitabine and gemcitabine administered as single agents, sequentially, for treatment of HER2-negative disease, trastuzumab (in combination with a taxane, vinorelbine or capecitabine) for patients with HER2-positive disease, and hormone therapies tamoxifen and anastrozole (as representative of the pharmacological class of aromatase inhibitors) for patients with hormone receptor-positive disease.

Cyclophosphamide, doxorubicin, paclitaxel, docetaxel and tamoxifen are currently included in the complementary list of the Model List. Vinorelbine, capecitabine, gemcitabine, trastuzumab and anastrozole were proposed for addition.

The application, amended to include details of the Expert Committee's considerations and decision, is presented in this section.

#### **Introduction**

Metastatic breast cancer is defined as disease beyond the breast and regional lymph nodes. Breast cancer can metastasize to any site in the body, including bones, liver, lung, serosal surfaces and brain. Although metastatic breast cancer is generally incurable, survival is highly variable: treatment is almost always indicated and patients can be treated and given palliative support with hormonal therapy, chemotherapy and/or targeted agents (1, 2).

Breast cancer is no longer viewed as a single disease but rather as a series of diseases defined by biological characteristics. Hormone receptor (HR) positive tumours demonstrate positivity for either estrogen receptors or progesterone receptors. Human epidermal growth factor receptor 2 (HER2) positive tumours overexpress the receptor HER2. Patients with HER2-positive disease typically have a worse prognosis.

Breast cancer can be viewed as four subtypes, as follows:

1. HR-positive/HER2-negative
2. HR-positive/HER2-positive
3. HR-negative/HER2-positive
4. HR-negative/HER2-negative.

These biological subtypes help predict which therapies are likely to be efficacious. Hormone therapy is beneficial only for patients with HR-positive tumours, and trastuzumab and similar HER2-targeted therapies are helpful only in patients with HER2-positive cancers.

## **Public health relevance**

Breast cancer comprises one-quarter of all new cancer cases worldwide including women and men, with an estimated 1.67 million cases in 2012 alone according to GLOBOCAN 2012, the database of the International Agency for Research on Cancer. Although highly treatable with systemic therapy, surgery and radiation therapy, breast cancer was the cause of death of approximately half a million women worldwide in 2012 (3). In sub-Saharan Africa alone, it is believed that nearly 50 000 women died from the disease during that one year. The ratio of incidence to mortality in high-, middle- and low-income countries varies dramatically, reflecting disparities in access to resources, clinical knowledge and medicines (as is the case for all cancers). According to one study in 2010, the 5-year survival rate for breast cancer ranged from 12% in Gambia, an extremely poor country, to 79% in the Republic of Korea, a high-income country (4). It has been noted that women suffering from breast cancer in the developing world are more likely to present to health facilities at later stages because of structural barriers to care, absence of treatment options, or inadequate information being disseminated to the public (5). Women who receive treatment for early-stage breast cancer have a significantly higher chance of survival than those treated for metastatic disease. Even in less developed regions of the world, overall survival at 5 years for women treated for localized disease was 73.6% on average, compared with 47.4% for regional disease (4).

## **Requirements for diagnosis, treatment, and monitoring**

### *Diagnostics*

The treatment of breast cancer should always be determined by pathological evaluation of the primary cancer. It is recommended that biopsy be performed by ultrasound-guided core needle technique, which will generally yield adequate tissue for histological and marker studies. Fine-needle aspiration can play a role but does not allow a distinction between in-situ and invasive cancer and often does not give adequate material for immunohistochemistry. Surgical excision should be required only rarely, if needle biopsy is technically not feasible. Evaluation of the biopsy by an experienced pathologist will yield the histological subtype and grade of the cancer. Immunohistochemistry (IHC) analysis for estrogen receptors, and in some cases progesterone receptors, is critical since this will determine prognosis and whether the cancer is potentially sensitive to hormone therapy. HER2 can be assessed by either IHC or by fluorescence in situ hybridization if IHC is equivocal.

### *Testing*

Staging should be performed to assess the extent of disease. Computerized tomography (CT) scans and bone scans can delineate the extent of metastatic disease. In more resource-constrained settings, a chest X-ray, liver ultrasound and plain films of bones that are painful are acceptable.

### *Administration and care of patients*

Hormone therapies (tamoxifen and aromatase inhibitors) are largely administered orally. No special testing or administrative resources are necessary for the use of these drugs, although a reliable supply is important.

Cytotoxic chemotherapy requires the ability to administer intravenous chemotherapy, with particular consideration of avoidance of extravasation with doxorubicin and of allergic reactions with taxanes. Chemotherapy can be administered in an outpatient infusion setting or an inpatient setting. Intravenous fluids and antiemetics, as well as hypersensitivity medications, are required. Monitoring of complete blood count, renal function, electrolytes and liver functions tests are required.

Trastuzumab and similar anti-HER2 targeted therapies are generally administered intravenously. Administration is relatively straightforward and is usually done in outpatient infusion facilities.

Cardiac monitoring is recommended for patients receiving trastuzumab or an anthracycline, although the incidence of serious cardiac toxicity is low – especially if anthracycline doses remain below cumulatively toxic levels – and the potential benefit in disease control is substantial.

As with all cancer treatment, social support, clean water and adequate nutrition are essential.

### **Overview of regimens**

The following provides basic information on administration and dosing for the four biological subtypes of breast cancer, followed by specific regimens.

#### *HR-positive/HER2-negative tumours*

Premenopausal patients should be treated initially with hormonal therapy, preferably tamoxifen, unless they were on tamoxifen at the time of the development of metastatic disease. Patients who are tolerating tamoxifen should be treated until there are clear signs of tumour progression. Stable disease is an indication to continue tamoxifen therapy. Aromatase inhibitors are not recommended for premenopausal women who should undergo either oophorectomy or ovarian suppression with a luteinizing hormone-releasing hormone agonist.

Women who are postmenopausal (naturally, surgically or chemically) can be treated with tamoxifen or an aromatase inhibitor. If they were on tamoxifen at the time of development of metastatic disease, they should be treated with an aromatase inhibitor. Treatment should continue until there is clear evidence of tumour progression, at which time the patient should be converted to the other agent (from tamoxifen to an aromatase inhibitor or vice versa). Stable disease is an indication to continue hormone therapy.

At the time of tumour progression, sequential single-agent chemotherapy should be used, unless there is rapidly progressive disease or high disease burden that requires a rapid

response, in which case combination chemotherapy can be used (1). Patients who were treated in the adjuvant setting with chemotherapy 12 months or less from the time of developing metastatic disease should be treated with chemotherapy agents other than those received in the adjuvant setting.

#### *HR-positive/HER2-positive tumours*

As above, hormone therapy should always be a component of the therapy for these patients; the factors that determine choice of therapy are the same as for patients with HR-positive/HER2-negative tumours.

Chemotherapy and trastuzumab should be initiated concurrently with hormone therapy. Typically trastuzumab is given concurrently with a taxane and not given concurrently with an anthracycline; however, trastuzumab can be given concurrently with other cytotoxic agents, such as vinorelbine.

#### *HR-negative/HER2-positive tumours*

Hormone therapy is not indicated. Trastuzumab chemotherapy combinations as described above for patients with HR-positive/HER2-positive tumours are indicated.

#### *HR-negative/HER2-negative tumours*

Hormone therapies and trastuzumab-containing regimens are not indicated for these patients. Sequential single-agent chemotherapy should be used, unless there is need for rapid control of disease due to visceral crisis or very high tumour burden (1, 6). The application stated that choice among recommended chemotherapeutic agents is arbitrary – there are no data to suggest that initial treatment with one agent is more efficacious than another. The only exception is that patients who were treated in the adjuvant setting with chemotherapy 12 months or less from the time of developing metastatic disease should be treated with agents other than those received in the adjuvant setting.

#### *Standard chemotherapy regimens (non-trastuzumab regimens)*

- **Doxorubicin, for subtypes 1 and 4 (and 2 and 3 if trastuzumab is unavailable)**
  - doxorubicin 60 mg/m<sup>2</sup> IV every 3 weeks
  - Note:* Cumulative dose of doxorubicin should not exceed 450 mg/m<sup>2</sup> because of the increased likelihood of severe cardiomyopathy with increasing dose.
- **Paclitaxel, for subtypes 1 and 4 (and 2 and 3 if trastuzumab is unavailable)**
  - paclitaxel 175 mg/m<sup>2</sup> IV every 3 weeks<sup>1</sup>
  - or
  - paclitaxel 80 mg/m<sup>2</sup> IV weekly

---

<sup>1</sup> Weekly paclitaxel is the more efficacious option but requires more frequent visits.

### *Standard regimens including trastuzumab, for HER2-positive disease*

- **Paclitaxel and trastuzumab, for subtypes 2 and 3**
  - paclitaxel 80 mg/m<sup>2</sup> IV weekly
  - trastuzumab 2 mg/kg IV weekly (following loading dose of 4mg/kg)
  
- **Docetaxel and trastuzumab, for subtypes 2 and 3**
  - docetaxel 60–75 mg/m<sup>2</sup> IV every 3 weeks
  - trastuzumab 6 mg/kg IV every 3 weeks (following loading dose of 8mg/kg)

### *Single-agent chemotherapy regimens, for HER2-negative disease*

The application stated that capecitabine, vinorelbine and gemcitabine have all been shown to have activity for patients with metastatic breast cancer, and can be supported to be given as single agents for patients with HER2-negative breast cancer. For patients with HER2-positive breast cancer trastuzumab has also been given with vinorelbine, successfully. These regimens are listed below.

- **Capecitabine (single agent)**
  - capecitabine 2000 mg/m<sup>2</sup> per day orally in two divided doses on days 1–14 of 21-day cycle
  
- **Vinorelbine (single agent)**
  - vinorelbine 25 mg/m<sup>2</sup> IV weekly
  
- **Gemcitabine (single agent)**
  - gemcitabine 1000 mg/m<sup>2</sup> IV on days 1 and 8 of 21-day cycle
  
- **Cyclophosphamide (single agent)**
  - cyclophosphamide 1000 mg/m<sup>2</sup> IV on day 1 of a 21-day cycle

Capecitabine is an alternative to paclitaxel in patients for whom anthracycline treatment has failed and for elderly patients or women wishing to avoid the adverse effects associated with cyclophosphamide, methotrexate and fluorouracil (7). Compared indirectly with vinorelbine, capecitabine was associated with lower costs and improved patient outcomes (8). Vinorelbine has a similar efficacy and toxicity profile to standard first-line chemotherapy with anthracyclines and other non-taxane-containing regimens (9).

### *Single-agent chemotherapy regimens, for HER2-positive disease*

- **Vinorelbine (with trastuzumab)**
  - vinorelbine 25 mg/m<sup>2</sup> IV weekly  
*with either*
  - trastuzumab 2 mg/kg IV weekly (following loading dose of 4mg/kg)
  - or
  - trastuzumab 6 mg/kg IV every 3 weeks (following loading dose of 8mg/kg)

### *Standard hormone regimens*

- tamoxifen 20 mg/day orally until tumour progression
- or
- anastrozole 1 mg/day orally until tumour progression

Aromatase inhibitors should be used only in postmenopausal women (natural or surgical) or premenopausal women who are receiving ovarian suppression.

Premenopausal women should receive tamoxifen, in addition to ovarian ablation (surgical) or ovarian suppression, until tumour progression. Postmenopausal women can be treated with either tamoxifen or an aromatase inhibitor, but not both concurrently. If there is tumour progression during treatment with one of these agents, that agent should be stopped and the other initiated. Sequential use of these agents results in increased survival and improved quality of life: delay in time to tumour progression results in increased time until use of chemotherapy becomes necessary (10).

### **Review of benefits and harms**

#### *Benefits*

Hormone therapy will yield clinical benefit for approximately half of the patients who have tumours that are estrogen- and/or progesterone-receptor-positive. Clinical benefit is defined by either reduction in tumour size or disease stability for at least several months. Patients who experience clinical benefit generally have a reduction in symptoms, improved quality of life and prolonged survival.

For about one third of patients who have had progressive disease on hormone therapy or have estrogen- and/or progesterone-receptor-negative disease, chemotherapy can lead to a reduction in tumour burden. Patients who benefit from chemotherapy have a reduction in symptoms, improved quality of life and a modest prolongation of survival.

A 2013 Cochrane systematic review of 12 trials comparing combination with sequential single-agent chemotherapy for metastatic breast cancer found there to be no difference in overall survival between the two groups (hazard ratio (HR) 1.04; 95% CI: 0.93–1.16;  $P = 0.45$ ). The review also found some evidence of a higher risk of progression in the combination arm (HR 1.11; 95% CI: 0.99–1.25;  $P = 0.08$ ). Overall tumour response rates were higher in the combination arm (RR 1.16; 95% CI: 1.06–1.28;  $P = 0.001$ ), as was the risk of febrile neutropenia (risk ratio (RR) 1.32; 95% CI: 1.06–1.65;  $P = 0.01$ ). The authors concluded that the findings supported recommendations in international guidelines for the use of sequential monotherapy unless there is rapid disease progression (6).

The Expert Committee considered that the evidence showed that gemcitabine is not a highly effective treatment for metastatic breast cancer. A meta-analysis of nine randomized controlled trials (2651 patients) revealed that, compared with gemcitabine-free chemotherapy, gemcitabine-based therapy offered no improvement in terms of time to

progression (HR 0.91; 95% CI: 0.72–1.15;  $P = 0.44$ ) or overall survival (HR 1.05; 95% CI: 0.88–1.25;  $P = 0.60$ ) (11). The rates of grade 3 and 4 anaemia (HR 2.02; 95% CI: 1.35–3.02;  $P = 0.006$ ), neutropenia (HR 2.33; 95% CI: 1.37–3.63;  $P = 0.01$ ) and thrombocytopenia (HR 8.31; 95% CI: 5.00–13.82;  $P < 0.0001$ ) were significantly higher in the gemcitabine-based arm. The authors concluded that gemcitabine-based chemotherapy was as effective as gemcitabine-free chemotherapy in patients with metastatic breast cancer but with increased haematological toxicity.

For patients with HER2-positive disease, the addition of trastuzumab to chemotherapy dramatically increases the response rate and overall survival. Typically, trastuzumab is given concurrently with a taxane, but patients may be treated with trastuzumab and vinorelbine or capecitabine (1).

A Cochrane systematic review of seven randomized controlled trials comparing trastuzumab alone or in combination with chemotherapy, hormonal therapy or targeted agents against the same regimen without trastuzumab (control) in 1497 women with HER2-positive metastatic breast cancer reported that adjuvant trastuzumab as first-line treatment improves survival but may increase the risk of heart failure (12). Trastuzumab-containing regimens were favoured for overall survival and progression-free survival (HR 0.82; 95% CI: 0.71–0.94,  $P = 0.004$ ; and HR 0.61; 95% CI: 0.54–0.70,  $P < 0.00001$ , respectively; moderate-quality evidence). Trastuzumab was associated with increasing rates of heart failure (RR 3.49; 90% CI: 1.88–6.47,  $P = 0.0009$ ; moderate-quality evidence) and left ventricular ejection fraction decline (RR 2.65; 90% CI: 1.48–4.74;  $P = 0.006$ ). The authors concluded that studies that administered trastuzumab as first-line treatment, or along with a taxane-based regimen, improved mortality outcomes. The evidence to support the use of trastuzumab beyond progression is limited.

The Committee noted that, since submission of the application, final results of the CLEOPATRA study have been published (13). This study compared the efficacy and safety of pertuzumab, trastuzumab and docetaxel versus placebo, trastuzumab and docetaxel as first-line treatments in patients with HER2-positive metastatic breast cancer. Deaths were reported in 168/402 patients (41.8%) in the pertuzumab group and in 221/406 patients (54.4%) patients in the control group (HR favouring the pertuzumab group, 0.68; 95% CI: 0.56–0.84;  $P < 0.001$ ). The difference in median overall survival between the two groups was 15.7 months: 56.5 months (95% CI: 49.3 to not reached) in the pertuzumab group and 40.8 months (95% CI: 35.8–48.3) in the placebo group (HR favouring the pertuzumab group 0.68; 95% CI: 0.56–0.84;  $P < 0.001$ ). The Expert Committee considered that the CLEOPATRA results are notable for their clinical relevance, but further efficacy and safety data from clinical trials other than single sponsor-driven trials are needed. In particular, the Committee considered that additional evidence is needed in women previously exposed to trastuzumab in the adjuvant setting. Pertuzumab was neither proposed nor recommended for inclusion in the EML at this time.

## *Harms and toxicity considerations*

### **Common**

Risks of treatment include common short-term toxicities such as alopecia, neutropenia, fever and infection, and neuropathy (affecting 15–60% of patients) from taxanes. Paclitaxel and trastuzumab are both associated with infusion reactions in up to 30–40% of patients; most infusion reactions are mild and easily managed (14, 15).

Tamoxifen can cause hot flushes, mood changes and, rarely, thromboembolic disease and endometrial cancer; it generally has a positive effect on bone density. Aromatase inhibitors can cause hot flushes, mood changes, musculoskeletal complaints and bone loss.

Vinorelbine often causes severe neutropenia and granulocytopenia, which increase patients' risk of infection. Like other vinca alkaloids, vinorelbine also frequently causes constipation. It is a strong vesicant, and care must be taken to avoid extravasation and associated tissue damage (16).

Palmar–plantar erythrodysesthesia (hand–foot syndrome) is associated with capecitabine, with an increased incidence of up to 60% in patients treated with capecitabine. This adverse effect typically resolves following interruption of treatment (17).

Gemcitabine frequently causes myelosuppression with dose-limiting thrombocytopenia and leukopenia with associated risk of infection. Gemcitabine is also associated with increased hepatic transaminases, which may lead to more severe hepatotoxicity in up to 10% of patients. Many patients experience oedema and dyspnoea (18).

### **Serious**

Cardiac muscle suppression or cardiac damage can occur after therapy with anthracyclines and trastuzumab, and administration of both agents together increases the risk. For the regimens described above, the risk of congestive heart failure is small and reversible upon discontinuation in most cases (19–21). Rare incidences of bone marrow damage, myelodysplastic syndrome and acute leukaemia can occur after therapy with doxorubicin. Diarrhoea occurs in up to 50% of patients treated with capecitabine. Diarrhoea can be severe, may require hospital admission for intravenous fluid replacement and is often dose-limiting (22).

### **Recommendations**

On the basis of the evidence presented in the application, the Committee made the following recommendations in relation to treatments for metastatic breast cancer:

- Trastuzumab should be added to the complementary list of the EML for the treatment of HER2-positive metastatic breast cancer.
- Capecitabine and intravenous vinorelbine should be added to the complementary list of the EML for the treatment of metastatic breast cancer. The Committee noted that orally administered vinorelbine is better tolerated but is more costly, so

recommended inclusion only of the intravenous formulation of vinorelbine at this time.

- Doxorubicin, paclitaxel, docetaxel and cyclophosphamide, currently on the complementary list, should be endorsed for use in the treatment of metastatic breast cancer.
- Tamoxifen should be specifically endorsed for treatment of HR-positive metastatic breast cancer.
- Anastrozole should be added to the complementary Model List for treatment of HR-positive metastatic breast cancer, with a square box symbol as representative of the therapeutic class of aromatase inhibitors.
- Inclusion of gemcitabine on the Model List is not recommended at this time, as the available evidence did not support an advantage of gemcitabine-based therapy over gemcitabine-free therapy in terms of time to progression and overall survival.

1. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). *Breast*. 2014;23(5):489-502.
2. Stage IIIIV, Inoperable IIIC, IV, Recurrent and Metastatic Breast Cancer [website] Bethesda, MD: National Cancer Institute; 2015 [Available from: <http://www.cancer.gov/types/breast/hp/breast-treatment-pdq#section/203>].
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013 [Available from: <http://globocan.iarc.fr>].
4. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. *Lancet Oncol*. 2010;11(2):165-73.
5. Anderson BO, Cazap E, El Saghir NS, Yip CH, Khaled HM, Otero IV, et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. *Lancet Oncol*. 2011;12(4):387-98.
6. Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. *Cochrane Database Syst Rev*. 2013;12:CD008792.
7. Tomiak E, Verma S, Levine M, Pritchard K, Sawka C, Breast Cancer Disease Site Group. Use of capecitabine in state IV breast cancer: an evidence summary. *Current Oncology*. 2000;7(2):84-90.
8. Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. *Health Technol Assess*. 2004;8(5):iii, xiii-xvi, 1-143.
9. Lewis R, Bagnall AM, King S, Woolacott N, Forbes C, Shirran L, et al. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. *Health Technol Assess*. 2002;6(14):1-269.

10. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. *J Clin Oncol*. 2003;21(11):2101-9.
11. Li W, Wang H, Li X. Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials. *Curr Med Res Opin*. 2013;29(11):1443-52.
12. Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, et al. Trastuzumab-containing regimens for metastatic breast cancer. *Cochrane Database Syst Rev*. 2014;6:CD006242.
13. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*. 2015;372(8):724-34.
14. Castells M, Matulonis U. Infusion reactions to systemic chemotherapy. In: UpToDate [website]. Waltham, MA: UpToDate; 2014.
15. LaCasce AS, Castells MC, Burnstein H, Meyerhardt JA. Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy. In: UpToDate [website]. Waltham, MA: UpToDate; 2014.
16. Vinorelbine. DrugPoints Summary. Micromedex 2.0. Greenwood Village, CO: Truven Health Analytics Inc.; 2012-2015.
17. Payne AS, Savarese DMF. Cutaneous complications of conventional chemotherapy agents. In: UpToDate [website]. Waltham, MA: UpToDate; 2014.
18. Gemcitabine. DrugPoints Summary. Micromedex 2.0. Greenwood Village, CO: Truven Health Analytics, Inc.; 2012-2015.
19. Floyd J, Morgan JP. Cardiotoxicity of anthracycline-like chemotherapy agents. In: UpToDate [website]. Waltham, MA: UpToDate; 2014.
20. Perez EA, Morgan JP. Cardiotoxicity of trastuzumab and other HER2-targeted agents. In: UpToDate [website]. Waltham, MA: UpToDate; 2014.
21. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. *J Clin Oncol*. 2004;22(2):322-9.
22. Krishnamurthi SS. Enterotoxicity of chemotherapeutic agents. In: UpToDate [website]. Waltham, MA: UpToDate; 2014.